نتایج جستجو برای: thiacetazone

تعداد نتایج: 60  

Journal: :PLoS ONE 2007
Anuradha Alahari Xavier Trivelli Yann Guérardel Lynn G. Dover Gurdyal S. Besra James C. Sacchettini Robert C. Reynolds Geoffrey D. Coxon Laurent Kremer

BACKGROUND Mycolic acids are a complex mixture of branched, long-chain fatty acids, representing key components of the highly hydrophobic mycobacterial cell wall. Pathogenic mycobacteria carry mycolic acid sub-types that contain cyclopropane rings. Double bonds at specific sites on mycolic acid precursors are modified by the action of cyclopropane mycolic acid synthases (CMASs). The latter belo...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2009
Asvi A Francois Clinton R Nishida Paul R Ortiz de Montellano Ian R Phillips Elizabeth A Shephard

The second-line antitubercular drugs thiacetazone (TAZ) and ethionamide (ETA) are bioactivated by the mycobacterial enzyme EtaA. We report here that human flavin-containing monooxygenase 2.1 (FMO2.1), which is expressed predominantly in the lung, catalyzes oxygenation of TAZ. The metabolites generated, the sulfenic acid, sulfinic acid, and carbodiimide derivatives, are the same as those produce...

Journal: :The Journal of biological chemistry 2012
Anna E Grzegorzewicz Jana Korduláková Victoria Jones Sarah E M Born Juan M Belardinelli Adrien Vaquié Vijay A K B Gundi Jan Madacki Nawel Slama Françoise Laval Julien Vaubourgeix Rebecca M Crew Brigitte Gicquel Mamadou Daffé Hector R Morbidoni Patrick J Brennan Annaik Quémard Michael R McNeil Mary Jackson

Isoxyl (ISO) and thiacetazone (TAC), two prodrugs once used in the clinical treatment of tuberculosis, have long been thought to abolish Mycobacterium tuberculosis (M. tuberculosis) growth through the inhibition of mycolic acid biosynthesis, but their respective targets in this pathway have remained elusive. Here we show that treating M. tuberculosis with ISO or TAC results in both cases in the...

Journal: :Antimicrobial agents and chemotherapy 2007
Lynn G Dover Anuradha Alahari Paul Gratraud Jessica M Gomes Veemal Bhowruth Robert C Reynolds Gurdyal S Besra Laurent Kremer

Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets. Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogues...

2013
Geoffrey D. Coxon Derek Craig Rosa Milagros Corrales Emilie Vialla Laila Gannoun-Zaki Laurent Kremer

Defining the pharmacological target(s) of currently used drugs and developing new analogues with greater potency are both important aspects of the search for agents that are effective against drug-sensitive and drug-resistant Mycobacterium tuberculosis. Thiacetazone (TAC) is an anti-tubercular drug that was formerly used in conjunction with isoniazid, but removed from the antitubercular chemoth...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید